Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Vortioxetine for Cognitive Dysfunction in MDD
NCT01422213Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Dec 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Dec 2011; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01422213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422213.